MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
OraSure Technologies Operating Income 2011-2026 | OSUR
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income OraSure Technologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -28.2 M | 32.7 M | -22.2 M | -10.2 M | -5.18 M | 18.6 M | 28.4 M | 40.2 M | 20.3 M | 8.06 M | -4.8 M | -12.2 M | -16.3 M | -9.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 40.2 M | -28.2 M | 2.85 M |
Quarterly Operating Income OraSure Technologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.1 M | -18 M | -17.8 M | - | -6 M | -2.74 M | -7.09 M | - | 10.9 M | -6.43 M | 24.3 M | - | 875 K | -21.5 M | -16.2 M | - | -13 M | 1.8 M | 10.4 M | - | 4.38 M | -9.4 M | -8.05 M | 4.08 M | 13.1 M | 5.28 M | -3.81 M | 12.5 M | 10.9 M | 5.56 M | -498 K | 10.2 M | 7.32 M | 6.89 M | 15.9 M | 7.07 M | 6.14 M | 4.35 M | 2.7 M | 4.09 M | 1.54 M | 2.72 M | -291 K | -2.56 M | 882 K | 2.5 M | -5.62 M | 6.06 M | -2.06 M | -5.58 M | -10.6 M | -6.15 M | -2.93 M | -3.54 M | -3.65 M | -281 K | -4.2 M | -2.36 M | -2.55 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 24.3 M | -21.5 M | -307 K |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
14 M | $ 20.66 | 1.27 % | $ 10.5 B | USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 205.09 | 1.16 % | $ 59 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-10.5 M | $ 8.15 | -7.6 % | $ 164 M | USA |
 |
Harvard Bioscience
HBIO
|
1.89 M | $ 0.66 | -1.92 % | $ 28 M | USA |
 |
iRhythm Technologies
IRTC
|
-116 M | $ 188.16 | 0.41 % | $ 5.87 B | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 138.18 | 0.8 % | $ 7.36 B | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 84.98 | 2.36 % | $ 4.28 B | USA |
 |
Alcon
ALC
|
580 M | $ 80.67 | -0.38 % | $ 40.4 B |  Schweiz |
 |
Predictive Oncology
POAI
|
-10.9 M | $ 6.85 | 3.24 % | $ 37.4 M | USA |
 |
AtriCure
ATRC
|
-40 M | $ 42.59 | 1.96 % | $ 2 B | USA |
 |
electroCore
ECOR
|
-19.3 M | $ 5.15 | 6.19 % | $ 28.4 K | USA |
 |
ICU Medical
ICUI
|
43 M | $ 152.88 | 1.7 % | $ 3.73 B | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 10.02 | -8.29 % | $ 409 M | USA |
 |
The Cooper Companies
COO
|
683 M | $ 83.38 | -0.63 % | $ 16.6 B | USA |
 |
Isoray
ISR
|
-90.9 M | - | 0.03 % | $ 108 M | USA |
 |
STERIS plc
STE
|
867 M | $ 260.64 | 0.52 % | $ 25.7 B | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 114.49 | 0.43 % | $ 5.55 B | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 8.9 | -0.11 % | $ 184 M | USA |
 |
Repro Med Systems
KRMD
|
-10.3 M | $ 5.79 | 3.02 % | $ 264 M | USA |
 |
LeMaitre Vascular
LMAT
|
52.3 M | $ 85.05 | 1.55 % | $ 1.91 B | USA |
 |
Intuitive Surgical
ISRG
|
2.35 B | $ 586.15 | -1.03 % | $ 208 B | USA |
 |
Merit Medical Systems
MMSI
|
156 M | $ 93.33 | 1.83 % | $ 5.43 B | USA |
 |
Utah Medical Products
UTMD
|
16.8 M | $ 58.5 | 1.39 % | $ 212 M | USA |
 |
Nephros
NEPH
|
-1.59 M | $ 5.07 | -1.74 % | $ 52.7 M | USA |
 |
Microbot Medical
MBOT
|
-9.86 M | $ 2.19 | 3.55 % | $ 22.3 M |  Israel |
 |
Milestone Scientific
MLSS
|
-6.76 M | $ 0.29 | 2.24 % | $ 23.1 M | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
-1.04 B | $ 23.52 | 2.53 % | $ 4.05 B | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 41.83 | 4.47 % | $ 138 M | USA |
 |
Pulse Biosciences
PLSE
|
-43.6 M | $ 14.71 | -3.26 % | $ 707 M | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 165.12 | -2.32 % | $ 9.2 M | USA |
 |
ResMed
RMD
|
1 B | $ 250.85 | 1.07 % | $ 36.6 B | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 24.91 | -1.97 % | $ 1.15 B | USA |
 |
Stereotaxis
STXS
|
-21.8 M | $ 2.57 | -1.35 % | $ 207 M | USA |
 |
Retractable Technologies
RVP
|
-21.1 M | $ 0.76 | -0.53 % | $ 22.8 M | USA |
 |
STAAR Surgical Company
STAA
|
-12.6 M | $ 22.43 | 1.08 % | $ 1.1 B | USA |
 |
Teleflex Incorporated
TFX
|
151 M | $ 110.0 | -13.07 % | $ 5.15 B | USA |
 |
West Pharmaceutical Services
WST
|
570 M | $ 274.0 | -1.62 % | $ 20 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-879 M | $ 12.53 | 1.25 % | $ 2.55 B | USA |